MedTrace Logo

AD816 Crossover Study

NCT05793684 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-11-15

No results posted yet for this study

Summary

The VicTor Study is a randomized, double blind, placebo-controlled, 3-period, multiple-dose crossover study in participants with OSA.

Conditions

Interventions

DRUG

Period A

Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo

DRUG

Period B

Week 1: AD816 low dose; Week 2: AD816 high dose

DRUG

Period C

Week 1: Placebo + Placebo; Week 2: Placebo + Placebo

Sponsors & Collaborators

  • Apnimed

    lead INDUSTRY

Principal Investigators

  • Ronald Farkas, MD · Apnimed Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-28
Primary Completion
2023-11-09
Completion
2023-11-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05793684 on ClinicalTrials.gov